Stocks
GoodRx Holdings Financial Statements (GDRX) |
||||||||||
| GoodRx Holdingssmart-lab.ru | % | 2020 | 2021 | 2022 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 12.03.2021 | 01.03.2022 | 31.12.2022 | 01.03.2023 | 29.02.2024 | 07.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 550.7 | 745.4 | 766.6 | 766.6 | 750.3 | 790.4 | |||
| Operating Income, bln rub | -275.7 | 13.4 | 1.74 | 11.0 | -27.0 | 46.0 | ||||
| EBITDA, bln rub | ? | -257.1 | 48.0 | 65.2 | 68.5 | 108.8 | 121.3 | |||
| Net profit, bln rub | ? | -293.6 | -25.3 | -32.8 | -32.8 | -8.87 | -7.92 | |||
| OCF, bln rub | ? | 131.3 | 178.8 | 146.8 | 146.8 | 138.3 | 155.0 | |||
| CAPEX, bln rub | ? | 35.8 | 34.5 | 55.2 | 55.2 | 55.8 | 87.5 | |||
| FCF, bln rub | ? | 95.5 | 144.3 | 91.6 | 91.6 | 82.5 | 141.1 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 4.39 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -55.3% | ||||
| OPEX, bln rub | 796.8 | 685.3 | 699.7 | 699.7 | 714.8 | 617.9 | ||||
| Cost of production, bln rub | 29.6 | 46.7 | 65.1 | 65.1 | 66.9 | 126.4 | ||||
| R&D, bln rub | 61.8 | 125.9 | 143.1 | 143.1 | 135.8 | 123.5 | ||||
| Interest expenses, bln rub | 27.9 | 23.6 | 34.2 | 34.2 | 56.7 | 56.4 | ||||
| Assets, bln rub | 1 470 | 1 608 | 1 605 | 1 605 | 1 589 | 1 355 | ||||
| Net Assets, bln rub | ? | 711.4 | 831.7 | 814.8 | 814.8 | 762.0 | 696.4 | |||
| Debt, bln rub | 704.9 | 702.3 | 65.2 | 717.0 | 711.1 | 57.0 | ||||
| Cash, bln rub | 968.7 | 941.1 | 757.2 | 757.2 | 672.3 | 423.8 | ||||
| Net debt, bln rub | -263.8 | -238.8 | -691.9 | -40.1 | 38.8 | -366.8 | ||||
| Ordinary share price, rub | 40.3 | 32.7 | 4.66 | 4.66 | 6.70 | 5.29 | ||||
| Number of ordinary shares, mln | 391.7 | 400.6 | 412.9 | 412.9 | 410.3 | 379.7 | ||||
| Market cap, bln rub | 15 800 | 13 090 | 1 924 | 1 924 | 2 749 | 2 008 | ||||
| EV, bln rub | ? | 15 536 | 12 852 | 1 232 | 1 884 | 2 788 | 1 642 | |||
| Book value, bln rub | 394 | 368 | 283 | 213 | 195 | 232 | ||||
| EPS, rub | ? | -0.75 | -0.06 | -0.08 | -0.08 | -0.02 | -0.02 | |||
| FCF/share, rub | 0.24 | 0.36 | 0.22 | 0.22 | 0.20 | 0.37 | ||||
| BV/share, rub | 1.00 | 0.92 | 0.69 | 0.52 | 0.47 | 0.61 | ||||
| EBITDA margin, % | ? | -46.7% | 6.44% | 8.50% | 8.94% | 14.5% | 15.4% | |||
| Net margin, % | ? | -53.3% | -3.39% | -4.28% | -4.28% | -1.18% | -1.00% | |||
| FCF yield, % | ? | 0.60% | 1.10% | 4.76% | 4.76% | 3.00% | 7.02% | |||
| ROE, % | ? | -41.3% | -3.04% | -4.03% | -4.03% | -1.16% | -1.14% | |||
| ROA, % | ? | -20.0% | -1.57% | -2.05% | -2.05% | -0.56% | -0.58% | |||
| P/E | ? | -53.8 | -518.3 | -58.6 | -58.6 | -310.0 | -253.4 | |||
| P/FCF | 165.4 | 90.7 | 21.0 | 21.0 | 33.3 | 14.2 | ||||
| P/S | ? | 28.7 | 17.6 | 2.51 | 2.51 | 3.66 | 2.54 | |||
| P/BV | ? | 40.1 | 35.6 | 6.80 | 9.04 | 14.1 | 8.67 | |||
| EV/EBITDA | ? | -60.4 | 267.7 | 18.9 | 27.5 | 25.6 | 13.5 | |||
| Debt/EBITDA | 1.03 | -4.97 | -10.6 | -0.59 | 0.36 | -3.02 | ||||
| R&D/CAPEX, % | 172.6% | 365.3% | 259.2% | 259.2% | 243.6% | 141.2% | ||||
| CAPEX/Revenue, % | 6.51% | 4.62% | 7.20% | 7.20% | 7.43% | 11.1% | ||||
| GoodRx Holdings shareholders | ||||||||||
